Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114

Diabetes Care. 2016 Dec;39(12):e224-e225. doi: 10.2337/dc16-1588.

Jens Jordan¹, Ali El-Armouche², Markolf Hanefeld³, Stefan R Bornstein^{4

5

6}, Andreas L Birkenfeld^{7

4

5

6}

¹ Department of Clinical Pharmacology, Medizinische Hochschule Hannover, Hannover, Germany.
² Department of Pharmacology, Technische Universität Dresden, Dresden, Germany.
³ Clinical Study Centre Professor Hanefeld, GWT TU-Dresden GmbH, Dresden, Germany.
⁴ Medical Clinic III, Universitätsklinikum "Carl Gustav Carus," Paul Langerhans Institute Dresden, Technische Universität Dresden, Dresden, Germany.
⁵ German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
⁶ Division of Diabetes and Nutritional Sciences, Rayne Institute, King's College London, London, U.K.
⁷ Clinical Study Centre Professor Hanefeld, GWT TU-Dresden GmbH, Dresden, Germany [email protected].

No abstract available

Publication types